AU2016318158B2 - Anti-survivin antibodies for cancer therapy - Google Patents

Anti-survivin antibodies for cancer therapy Download PDF

Info

Publication number
AU2016318158B2
AU2016318158B2 AU2016318158A AU2016318158A AU2016318158B2 AU 2016318158 B2 AU2016318158 B2 AU 2016318158B2 AU 2016318158 A AU2016318158 A AU 2016318158A AU 2016318158 A AU2016318158 A AU 2016318158A AU 2016318158 B2 AU2016318158 B2 AU 2016318158B2
Authority
AU
Australia
Prior art keywords
gly
ser
glu
pro
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016318158A
Other languages
English (en)
Other versions
AU2016318158A1 (en
Inventor
Michael J. Ciesielski
Robert A. Fenstermaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of AU2016318158A1 publication Critical patent/AU2016318158A1/en
Application granted granted Critical
Publication of AU2016318158B2 publication Critical patent/AU2016318158B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016318158A 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy Active AU2016318158B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214242P 2015-09-04 2015-09-04
US62/214,242 2015-09-04
PCT/US2016/050391 WO2017041092A2 (en) 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy

Publications (2)

Publication Number Publication Date
AU2016318158A1 AU2016318158A1 (en) 2018-04-05
AU2016318158B2 true AU2016318158B2 (en) 2022-09-15

Family

ID=58188638

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016318158A Active AU2016318158B2 (en) 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy

Country Status (10)

Country Link
US (3) US10167340B2 (enExample)
EP (1) EP3344287B1 (enExample)
JP (1) JP6831836B2 (enExample)
KR (1) KR102773176B1 (enExample)
CN (1) CN108883163B (enExample)
AU (1) AU2016318158B2 (enExample)
CA (1) CA2997103A1 (enExample)
DK (1) DK3344287T3 (enExample)
ES (1) ES2883128T3 (enExample)
WO (1) WO2017041092A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203732A1 (en) * 2020-12-31 2022-07-07 Health Research, Inc. Anti-survivin antibodies for treatment of autoimmune diseases
CN120028549B (zh) * 2023-11-23 2025-11-28 爱威科技股份有限公司 检测丙型肝炎病毒核心蛋白结合蛋白6的试剂盒及应用
CN120025432A (zh) * 2023-11-23 2025-05-23 爱威科技股份有限公司 Hcbp6单克隆抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012460A1 (en) * 2007-07-19 2009-01-22 Health Research, Inc. Survivin peptides as cancer vaccines
US20090286312A1 (en) * 2006-01-13 2009-11-19 Novartis Ag Methods and Compositions for Treating Allergic Diseases
US20110136743A1 (en) * 1996-11-20 2011-06-09 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US20120082667A1 (en) * 2009-04-17 2012-04-05 Immunas Pharma, Inc. Antibodies That Specifically Bind To A Beta Oligomers And Use Thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2001046455A2 (en) * 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US20040110930A1 (en) * 2002-10-03 2004-06-10 Reinl Stephen J. Multimeric protein engineering
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
PE20090722A1 (es) * 2007-02-02 2009-07-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US8580269B2 (en) 2007-07-19 2013-11-12 Health Research, Inc. Survivin peptides for autoimmune therapies
CA2898457A1 (en) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Ovarian cancer vaccines and vaccination methods
CN104098696A (zh) * 2013-04-07 2014-10-15 中美华世通生物医药科技（武汉）有限公司 一种抗血管内皮生长因子的单克隆抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136743A1 (en) * 1996-11-20 2011-06-09 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US20090286312A1 (en) * 2006-01-13 2009-11-19 Novartis Ag Methods and Compositions for Treating Allergic Diseases
WO2009012460A1 (en) * 2007-07-19 2009-01-22 Health Research, Inc. Survivin peptides as cancer vaccines
US20120082667A1 (en) * 2009-04-17 2012-04-05 Immunas Pharma, Inc. Antibodies That Specifically Bind To A Beta Oligomers And Use Thereof

Also Published As

Publication number Publication date
CA2997103A1 (en) 2017-03-09
KR20180042431A (ko) 2018-04-25
WO2017041092A3 (en) 2017-05-11
ES2883128T3 (es) 2021-12-07
DK3344287T3 (da) 2021-07-19
JP2018529672A (ja) 2018-10-11
WO2017041092A2 (en) 2017-03-09
US10738129B2 (en) 2020-08-11
US20200377613A1 (en) 2020-12-03
JP6831836B2 (ja) 2021-02-17
US10167340B2 (en) 2019-01-01
US20170066837A1 (en) 2017-03-09
US20190119398A1 (en) 2019-04-25
EP3344287A2 (en) 2018-07-11
EP3344287A4 (en) 2019-04-24
AU2016318158A1 (en) 2018-04-05
EP3344287B1 (en) 2021-05-26
KR102773176B1 (ko) 2025-02-27
CN108883163A (zh) 2018-11-23
CN108883163B (zh) 2022-04-15
US11773181B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
TWI757304B (zh) Lag-3抗體、其抗原結合片段及其醫藥用途
US11773181B2 (en) Anti-survivin antibodies for cancer therapy
TWI843799B (zh) 抗pd-1抗體、其抗原結合片段及醫藥用途
TW202017945A (zh) 抗ｃｄ７３抗體、其抗原結合片段及應用
AU2015231256A1 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2017215585A1 (zh) 抗cd47单克隆抗体及其应用
JP7526493B2 (ja) Ｌｒｉｇ－１タンパク質に特異的な結合分子及びその用途
JP6635599B2 (ja) 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
US20240190986A1 (en) Mesothelin binding molecule and application thereof
CN114685666B (zh) 抗间皮素纳米抗体及其应用
CN118206660A (zh) 间皮素结合分子及其应用
WO2022023292A9 (en) Corona virus spike protein-targeting antibodies and use thereof
WO2021043810A1 (en) Anti-fucosyl-gm1 antibodies
KR20150084007A (ko) 항-프로키네티신 수용체 (ｐｒｏｋｒ) 항체 및 이의 용도
US20240317844A1 (en) Anti-survivin antibodies for treatment of autoimmune diseases
CN120988130A (zh) Siglec-15特异性单克隆抗体的制备及抗肿瘤效应
HK40051455B (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)